Kirsten Fallon
CorpComms@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 16, 2021•Six women reflect on their period experiences and journeys to self-advocacy in new video series
RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) — HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences...
-
Jan 5, 2021
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™...
-
Dec 28, 2020•Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
NEW YORK and LONDON, Dec. 28, 2020 (GLOBE NEWSWIRE) — Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a healthcare...
-
Dec 23, 2020•GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dec. 23, 2020– Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug...
-
Dec 17, 2020•ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and...